MapLight Therapeutics — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ML-007C-MAML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).	Alzheimer	Phase 2	À vérifier	United States, Argentina, Bulgaria, Canada, Czechia, France, Hungary, Italy, …	À vérifier
ML-007C-MAML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).	Alzheimer	Phase 2	À vérifier	United States, Bulgaria, France	À vérifier
ML-007C-MAML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).	Alzheimer	Phase 2	À vérifier	United States, Argentina, Bulgaria, Canada, Czechia, France, Hungary, Italy, Poland, Portugal, Romania, Serbia, Slovakia, South Korea	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
ML-007C-MA	Alzheimer	Phase 2	NCT06887192	A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis	RECRUITING
ML-007C-MA	Alzheimer	Phase 2	NCT07459660	An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis	ENROLLING_BY_INVITATION

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.